All In Biotech

Company · NBIX

Neurocrine Biosciences

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Neurocrine Biosciences.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

4

4 still marketed

Novel approvals

2

Approvals since 2021

5

Originals and new uses

Phase 3 trials

23

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Crenessity approved Breakthrough therapyPriority reviewOrphanDec 13, 2024
  • Crenessity approved NovelBreakthrough therapyPriority reviewOrphanDec 13, 2024
  • Ingrezza Sprinkle approved OrphanApr 30, 2024
  • Ingrezza new use OrphanAug 18, 2023
  • Ingrezza new use Apr 23, 2021
  • Ingrezza approved NovelBreakthrough therapyPriority reviewOrphanApr 11, 2017

Drugs in development (7)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (4)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.